OLIG2 is a Novel Immunohistochemical Marker Associated with the Presence of PAX3/7-FOXO1 Translocation in Rhabdomyosarcomas

Overview

Journal Diagn Pathol

Publisher Biomed Central

Specialty Pathology

Date 2019 Sep 9

PMID 31493794

Citations 4

Authors

Magdalena Kaleta

Anna Wakulinska

Agnieszka Karkucinska-Wieckowska

Bozenna Dembowska-Baginska

Wieslawa Grajkowska

Maciej Pronicki

Maria Lastowska

Affiliations

Soon will be listed here.

Abstract

Background: The most frequent histological types of rhabdomyosarcoma (RMS) in children are embryonal (ERMS) and alveolar (ARMS) tumours. The majority of ARMS are characterized by the presence of PAX3/7-FOXO1 gene fusion and have a worse prognosis than fusion gene-negative ARMS. However, identification of PAX3/7-FOXO1 fusion status is challenging when using formalin-fixed, paraffin-embedded (FFPE) material. Microarray analyses revealed that high expression of several genes is associated with PAX3/7-FOXO1 fusion status. Therefore, we investigated if immunohistochemical approach may detect surrogate marker genes as indicators of fusion gene-positive RMS.

Methods: Forty five RMS patients were included in the analysis and immunohistochemistry was applied to FFPE tissues collected at diagnosis. Protein expression of OLIG2, a novel marker in RMS, was investigated using antibody EP112 (Cell Marque). In addition already known two markers were also analyzed: TFAP2B using rabbit anti-TFAP2β antibody (Santa Cruz Biotechnology) and ALK using anti-ALK antibody clone D5F3 #3633 (Cell Signalling). Fluorescence in situ hybridization (FISH) was performed on FFPE sections with FOXO1/PAX3 and/or FOXO1/PAX7 probes (Dual Colour Single Fusion Probe, Zytovision).

Results: Our analysis revealed that all three immunohistochemical markers are associated with the presence of PAX3/7-FOXO1 fusion: TFAP2B (p < 0.00001), OLIG2 (p = 0.0001) and ALK (p = 0.0007). Four ARMS had negative PAX3/7-FOXO1 status and none of them displayed positive reaction with the analysed markers. Positive reaction with OLIG2 (6 tumours) was always associated with the presence of PAX3/7-FOXO1 rearrangement. Two additional OLIG2 positive cases showed inconclusive FISH results, but were positive for TFAP2B and ALK, what suggests that these tumours expressed fusion positive signature.

Conclusion: Our results indicate that TFAP2B, ALK and a novel marker OLIG2 may serve as surrogate markers for PAX3/7-FOXO1 status what is especially beneficial in cases where poor quality tumour tissue is not suitable for reliable genetic analyses or shows inconclusive result.

Citing Articles

A rare adult case of primary uterine rhabdomyosarcoma with mixed pattern: a clinicopathological & immunohistochemical study with literature review.

Kamel N, Hasby E Diagn Pathol. 2024; 19(1):98.

PMID: 39020398 PMC: 11253370. DOI: 10.1186/s13000-024-01518-w.

Sarcoma_CellminerCDB: A tool to interrogate the genomic and functional characteristics of a comprehensive collection of sarcoma cell lines.

Tlemsani C, Heske C, Elloumi F, Pongor L, Khandagale P, Varma S iScience. 2024; 27(6):109781.

PMID: 38868205 PMC: 11167437. DOI: 10.1016/j.isci.2024.109781.

Hedgehog pathway in sarcoma: from preclinical mechanism to clinical application.

Banaszek N, Kurpiewska D, Kozak K, Rutkowski P, Sobczuk P J Cancer Res Clin Oncol. 2023; 149(19):17635-17649.

PMID: 37815662 PMC: 10657326. DOI: 10.1007/s00432-023-05441-3.

S-100 Immunohistochemical Positivity in Rhabdomyoma: An Underestimated Potential Diagnostic Pitfall in Routine Practice.

Palicelli A, Ramponi A, Valente G, Boldorini R, Balbo Mussetto A, Zanelli M Diagnostics (Basel). 2022; 12(4).

PMID: 35453940 PMC: 9030831. DOI: 10.3390/diagnostics12040892.

References

Anderson J, Gordon T, McManus A, Mapp T, Gould S, Kelsey A . Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?. Br J Cancer. 2001; 85(6):831-5. PMC: 2375077. DOI: 10.1054/bjoc.2001.2008. View

Chi N, Epstein J . Getting your Pax straight: Pax proteins in development and disease. Trends Genet. 2001; 18(1):41-7. DOI: 10.1016/s0168-9525(01)02594-x. View

Sorensen P, Lynch J, Qualman S, Tirabosco R, Lim J, Maurer H . PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol. 2002; 20(11):2672-9. DOI: 10.1200/JCO.2002.03.137. View

Wachtel M, Dettling M, Koscielniak E, Stegmaier S, Treuner J, Simon-Klingenstein K . Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res. 2004; 64(16):5539-45. DOI: 10.1158/0008-5472.CAN-04-0844. View

Meza J, Anderson J, Pappo A, Meyer W . Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol. 2006; 24(24):3844-51. DOI: 10.1200/JCO.2005.05.3801. View

Ebauer M, Wachtel M, Niggli F, Schafer B . Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene. 2007; 26(51):7267-81. DOI: 10.1038/sj.onc.1210525. View

Oberlin O, Rey A, Lyden E, Bisogno G, Stevens M, Meyer W . Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008; 26(14):2384-9. PMC: 4558625. DOI: 10.1200/JCO.2007.14.7207. View

Davicioni E, Anderson M, Graf Finckenstein F, Lynch J, Qualman S, Shimada H . Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol. 2009; 174(2):550-64. PMC: 2630563. DOI: 10.2353/ajpath.2009.080631. View

Williamson D, Missiaglia E, De Reynies A, Pierron G, Thuille B, Palenzuela G . Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol. 2010; 28(13):2151-8. DOI: 10.1200/JCO.2009.26.3814. View

10.

Cao L, Yu Y, Bilke S, Walker R, Mayeenuddin L, Azorsa D . Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res. 2010; 70(16):6497-508. PMC: 2922412. DOI: 10.1158/0008-5472.CAN-10-0582. View

11.

Liu J, Guzman M, Pezanowski D, Patel D, Hauptman J, Keisling M . FOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma. Mod Pathol. 2011; 24(10):1327-35. DOI: 10.1038/modpathol.2011.98. View

12.

Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F . PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol. 2012; 30(14):1670-7. DOI: 10.1200/JCO.2011.38.5591. View

13.

Yoshida A, Shibata T, Wakai S, Ushiku T, Tsuta K, Fukayama M . Anaplastic lymphoma kinase status in rhabdomyosarcomas. Mod Pathol. 2013; 26(6):772-81. DOI: 10.1038/modpathol.2012.222. View

14.

Skapek S, Anderson J, Barr F, Bridge J, Gastier-Foster J, Parham D . PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report. Pediatr Blood Cancer. 2013; 60(9):1411-7. PMC: 4646073. DOI: 10.1002/pbc.24532. View

15.

Fu L, Shi K, Wang J, Chen W, Shi D, Tian Y . TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF/PEDF signaling. Mol Cancer. 2014; 13:89. PMC: 4021500. DOI: 10.1186/1476-4598-13-89. View

16.

Sun W, Chatterjee B, Wang Y, Stevenson H, Edelman D, Meltzer P . Distinct methylation profiles characterize fusion-positive and fusion-negative rhabdomyosarcoma. Mod Pathol. 2015; 28(9):1214-24. PMC: 6345526. DOI: 10.1038/modpathol.2015.82. View

17.

Ikram F, Ackermann S, Kahlert Y, Volland R, Roels F, Engesser A . Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma. Mol Oncol. 2015; 10(2):344-59. PMC: 5528952. DOI: 10.1016/j.molonc.2015.10.020. View

18.

Gasparini P, Casanova M, Villa R, Collini P, Alaggio R, Zin A . Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma. Oncotarget. 2016; 7(37):58903-58914. PMC: 5312284. DOI: 10.18632/oncotarget.10368. View

19.

Zainolabidin N, Kamath S, Thanawalla A, Chen A . Distinct Activities of Tfap2A and Tfap2B in the Specification of GABAergic Interneurons in the Developing Cerebellum. Front Mol Neurosci. 2017; 10:281. PMC: 5583517. DOI: 10.3389/fnmol.2017.00281. View

20.

Gallego S, Zanetti I, Orbach D, Ranchere D, Shipley J, Zin A . Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer. 2018; 124(15):3201-3209. DOI: 10.1002/cncr.31553. View